EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response

Richard D Lutze, Matthew A Ingersoll, Alena Thotam, Anjali Joseph, Joshua Fernandes, Tal Teitz iD

International Journal of Molecular Sciences · 07.06.2024 · 25 (12) · 6305

DOI: 10.3390/ijms25126305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.06.2024. Verfasst von Richard D Lutze und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA. Hauptthemen laut MEDLINE: Hearing Loss, Noise-Induced. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, American Hearing Research Foundation, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Noise-induced hearing loss (NIHL) is a major cause of hearing impairment and is linked to dementia and mental health conditions, yet no FDA-approved drugs exist to prevent it. Downregulating the mitogen-activated protein kinase (MAPK) cellular pathway has emerged as a promising approach to attenuate NIHL, but the molecular targets and the mechanism of protection are not fully understood. Here, we tested specifically the role of the kinases ERK1/2 in noise otoprotection using a newly developed, highly specific ERK1/2 inhibitor, tizaterkib, in preclinical animal models. Tizaterkib is currently being tested in phase 1 clinical trials for cancer treatment and has high oral bioavailability and low predicted systemic toxicity in mice and humans. In this study, we performed dose–response measurements of tizaterkib’s efficacy against permanent NIHL in adult FVB/NJ mice, and its minimum effective dose (0.5 mg/kg/bw), therapeutic index (>50), and window of opportunity (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hearing Loss, Noise-InducedAnimalsMiceAdministration, OralMaleProtein Kinase InhibitorsMAP Kinase Signaling SystemFemaleDisease Models, AnimalCochlea

Stichwörter der Autor:innen

ERK1/2hearing protectionimmune responsenoise-induced hearing lossoral deliveryrepurposing drugs

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA.
  • The Scintillon Research Institute, San Diego, CA 92121, USA.

ORCID-Profile: Tal Teitz

Förderung

  • NIGMS NIH HHS
  • American Hearing Research Foundation
  • NCRR NIH HHS
  • NIDCD NIH HHS
  • NIH HHS
  • National Institutes of Health NIDCD
  • American Hearing Research Foundation 2020

Zitieren

APA

Lutze, R. D., Ingersoll, M. A., Thotam, A., Joseph, A., Fernandes, J., & Teitz, T. (2024). ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response. International Journal of Molecular Sciences, 25(12), 6305. https://doi.org/10.3390/ijms25126305

Vancouver

Lutze RD, Ingersoll MA, Thotam A, Joseph A, Fernandes J, Teitz T. ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response. International Journal of Molecular Sciences. 2024;25(12):6305. doi:10.3390/ijms25126305

BibTeX
@article{Lutze2024,
  author = {Lutze, Richard D and Ingersoll, Matthew A and Thotam, Alena and Joseph, Anjali and Fernandes, Joshua and Teitz, Tal},
  title = {ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {12},
  pages = {6305},
  doi = {10.3390/ijms25126305}
}
Kostenlos starten →